• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

MMF and rituximab combination effective in nephrotic syndrome

byNeha JoshiandCordelia Ross
June 22, 2015
in Nephrology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This retrospective analysis examined 24 children with steroid-resistant nephrotic syndrome, all initially treated with rituximab after failing traditional therapies (e.g. steroids, calcineurin inhibitors). 

2. Children treated with both rituximab and mycophenolate mofetil (MMF) were more likely to have sustained complete remission of their nephrotic syndrome compared to those treated with rituximab alone.

Evidence Rating Level: 2 (Good)

Study Rundown: Idiopathic nephrotic syndrome in children is usually treated with steroids as first-line therapy, with approximately an 80% remission rate. The remaining 20% with steroid-resistant nephrotic syndrome are at especially high risk for poor renal function. In these children, various immunosuppressive agents (e.g. cyclophosphamide, calcineurin-inhibitors) are then tried as second line therapy, though these therapies are sometimes limited in efficacy and by a significant side effect profile. Therefore, a third class of therapy – rituximab – has recently gained ground. Rituximab, a monoclonal antibody targeting CD20 cells, works by depleting B lymphocytes. Children with steroid-resistant nephrotic syndrome achieving remission on rituximab still remain at risk for further relapse. As such, this study used MMF as an immunosuppressive agent to maintain induced remission by rituximab. Results indicated higher likelihood of maintaining remission when treated with both rituximab and MMF compared to rituximab alone. Limitations of this study include its retrospective nature, small sample size, and inability to follow MMF drug levels in establishing therapeutic efficacy.

Click to read the study, published today in Pediatrics

Relevant Reading: Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO

In-Depth [retrospective analysis]: This study retrospectively examined 24 children between the ages of 2 and 16 years who have been diagnosed with idiopathic steroid-resistant nephrotic syndrome. Of the 24 children, 13 had minimal change disease and 11 had focal segmental glumerulosclerosis by histopathology. All children had initially received steroids and then calcineurin-inhibitors, without achieving sustained remission and/or experiencing significant side effects warranting cessation of therapy. Full remission was defined as normal urine protein to creatinine ratio of less than 0.2. Partial remission included urine protein to creatinine ratio of 0.2 to 2, serum albumin >2.5 g/dL, and no edema. These children initially all received rituximab, with course length dependent on achieving remission. Fifteen children were then started on MMF 3 months after receiving initial rituximab dose. At 6 months, 67% of those receiving MMF were in complete remission, while 33% were in partial remission. At 24 months, 33% of those receiving rituximab and MMF were in sustained complete remission (vs. 0% of children receiving rituximab alone), suggesting the effectiveness of adding MMF in steroid-resistant nephrotic syndrome. Of note, all children with sustained remission at 24 months had minimal change disease and were late steroid resistant, suggesting a possible favorable risk group.

RELATED REPORTS

Oral tacrolimus noninferior to intravenous cyclophosphamide for lupus nephritis

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: nephrologyrituximab
Previous Post

Publication of pneumonia antibiotic guidelines changed prescribing trends

Next Post

Primary seat belt laws associated with lower motor vehicle fatality

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Nephrology

Oral tacrolimus noninferior to intravenous cyclophosphamide for lupus nephritis

April 27, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Cardiology

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

April 20, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Ticagrelor reversal agent provides immediate and sustained effect
Weekly Rewinds

2 Minute Medicine Rewind February 28, 2022

February 28, 2022
Next Post
Primary seat belt laws associated with lower motor vehicle fatality

Primary seat belt laws associated with lower motor vehicle fatality

Device failure may contribute to sudden death with cardiac implanted devices

Device failure may contribute to sudden death with cardiac implanted devices

2 Minute Medicine Rewind June 15 – June 21, 2015

2 Minute Medicine Rewind June 15 – June 21, 2015

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.